Analysts’ Viewpoint on Glioma Treatment Market Scenario
Surge in number of surgeries performed across the globe and major technological innovations in radiation therapy for glioma, molecular therapies, chemotherapy, and targeted therapies are driving the global glioma treatment market. Furthermore, notable growth potential in emerging countries such as India, South Korea, and Brazil is projected to boost the glioma treatment market during the forecast period. However, less survival rate and lack of awareness are estimated to hamper the global market in the near future. Nevertheless, increase in investments by public & private organizations and entry of various startups into the glioma treatment market are likely to lead to positive sentiment among patients toward effective treatment.
Glioma is a condition that covers a broad category of brain and spinal cord tumors that affect the glial cells in the brain. Glioma can affect brain function and can be fatal depending on its location and severity of the tumor. Different types of gliomas are astrocytoma, brain stem gliomas, ependymomas, mixed gliomas (oligo-astrocytomas), oligodendrogliomas, and optic pathway gliomas. Common glioma symptoms include headache, nausea, vomiting, confusion, and decline in brain function. Various therapeutic options are available for the treatment of glioma. These include radiation therapy for glioma, chemotherapy, glioma targeted therapy, and surgery. Late stage clinical pipeline drugs can be effective treatment options for glioma.
Approval of late stage pipeline drug designation to certain molecules for the treatment of glioma is a major factor that is likely to drive the global glioma diagnosis and treatment market. For instance, on December 05, 2019, the U.S. FDA and European Medicines Agency granted orphan drug designation to Adastra Pharmaceuticals drug zotiraciclib, a multikinase inhibitor. This drug is being evaluated in two phase 1b clinical studies of patients with glioblastoma ‒ the most common glioma histology for the treatment of glioma. Rise in prevalence of brain cancer and increase in awareness regarding various types of gliomas are also fueling the global glioma treatment market. Moreover, strategic alliances for the development of glioma therapeutics products and increase in exposure of humans to radiation in the last few years, which leads to higher incidence of brain cancer, are some of the key factors propelling the global glioma therapy market.
The outbreak of COVID-19 has had a negative effect on the global glioma treatment market. Governments of affected countries gave instructions for the postponement of non-essential surgeries and patient visits. Surgical neuro-oncology is a specialty that created a dilemma in continuing surgical care during the pandemic. Several ICU facilities, such as ventilators, personal protective equipment, and medical staff, were rerouted to COVID-19 cases, prompting the suspension of surgical neuro-oncology services during the pandemic. Instability in the provision of adequate medical care to critically-ill cancer patients was witnessed during the pandemic. Additionally, glioblastoma patients are vulnerable to the COVID-19 infection, which led to postponement of treatments and surgeries. Thus, there was a decrease in Y-o-Y growth due to postponed brain surgeries in hospitals and ambulatory surgical centers during the COVID-19 outbreak.
In terms of type, the global glioma treatment market has been divided into low-grade gliomas and high-grade gliomas. High-grade gliomas is anticipated to be a highly lucrative segment in the near future due to the availability of more options for diagnosis and treatment of glioma tumor of this grade. High-grade gliomas are highly severe tumors and largely occur in children and adults. Various factors such as frequent radiation therapies, improper surgeries of the brain, and multiple therapies are expected to drive the market. Manufacturers are emphasizing on the use of innovative technologies, which is projected to fuel the segment in the near future. For instance, ASCO 2022 would get fresh clinical data on the usage of Kiyatec's ex vivo 3D cell culture technique for high-grade glioma. Furthermore, rise in prevalence and incidence of high-grade gliomas is driving the market. High-grade glioma is one of the frequently diagnosed primary brain tumors. According to the National Library of Medicine, the incidence rate of high-grade glioma is about 5.8 males and 4.1 females per 100,000 people per year.
Based on treatment, the surgery segment dominated the global glioma treatment market in 2021. This trend is projected to continue during the forecast period. Surgery to remove as many tumors as possible is usually the first step in treating most gliomas. In some cases, gliomas are small and can be easily removed from the surrounding healthy brain tissue, allowing for complete surgical removal. Moreover, presence of reimbursement policies that encourage healthcare providers to maintain quality infrastructure is expected to boost the surgery segment. Thus, increase in success rate of surgeries and reimbursement policies is expected to drive the surgery segment. Additionally, rise in number of surgical procedures for the treatment of glioma in growing economies, including China and India, is boosting the segment. Governments of China and India have increased their healthcare spend, which in turn is augmenting the admission of patients in hospitals.
In terms of region, North America dominated the global glioma treatment market in 2021. This can be ascribed to the rise in approval of new products for glioma treatment, higher prevalence of brain tumor cases, growing exposure of population to radiation, and presence of major companies in the region. For instance, according to stats by the American Society of Clinical Oncology (ASCO), an estimated 23,820 adults in the U.S. were diagnosed with primary cancerous tumors of the brain and spinal cord in 2018. Brain tumors accounted for 85% to 90% of all primary CNS tumors.
The market in Asia Pacific is expected to be highly lucrative during the forecast period due to the launch of approved products in the region in the latter half of the forecast period, higher geriatric population, increase in number of patients with cancer, and rise in awareness regarding diseases & treatment.
This report includes vital information about the key players operating in the global glioma treatment market. Key players are focusing on strategies such as new product launches, divestiture, mergers & acquisitions (M&A), and partnerships to consolidate their position in the market. Sun Pharmaceutical Industries Ltd., Amgen, Inc., Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Pfizer, Inc., Merck KGaA, and F. Hoffmann-La Roche Ltd. are the prominent players operating in the global glioma treatment market.
Each of these players has been profiled in the glioma treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 4.39 Bn |
|
Market Forecast Value in 2031 |
More than US$ 7.51 Bn |
|
Compound Annual Growth Rate (CAGR) |
5.7% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global glioma treatment market was valued at US$ 4.39 Bn in 2021.
The global glioma treatment market is projected to reach more than US$ 7.51 Bn by 2031.
The global glioma treatment market is anticipated to grow at a CAGR of 5.7% from 2022 to 2031.
Increase in drug approval for glioma treatment is driving the global glioma treatment market.
North America is expected to account for major share of the global glioma treatment market during the forecast period.
Sun Pharmaceutical Industries Ltd., Amgen, Inc., Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Pfizer, Inc., Merck KGaA, and F. Hoffmann-La Roche Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Glioma Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Glioma Treatment Market Analysis and Forecasts, 2017‒2031
5. Key Insights
5.1. Key Industry Events (Mergers & Acquisitions, Product Launches, Partnerships)
5.2. Pipeline Analysis
5.3. Low Grade Glioma: Overview
5.4. Disease Prevalence Rate & Incidence Rate Globally
5.5. Covid-19 Pandemic Impact on the Industry
6. Global Glioma Treatment Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017‒2031
6.3.1. Low-Grade
6.3.1.1. grade I
6.3.1.2. grade II
6.3.2. High-grade
6.3.2.1. grade III
6.3.2.2. grade IV
6.4. Market Attractiveness, by Type
7. Global Glioma Treatment Market Analysis and Forecast, by Treatment
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Treatment, 2017‒2031
7.3.1. Surgery
7.3.2. Radiation Therapy
7.3.3. Chemotherapy
7.3.4. Targeted Drug Therapy
7.3.5. Others
7.4. Market Attractiveness, by Treatment
8. Global Glioma Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Glioma Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Type, 2017‒2031
9.2.1. Low-Grade
9.2.1.1. grade I
9.2.1.2. grade II
9.2.2. High-grade
9.2.2.1. grade III
9.2.2.2. grade IV
9.3. Market Value Forecast, by Treatment, 2017‒2031
9.3.1. Surgery
9.3.2. Radiation Therapy
9.3.3. Chemotherapy
9.3.4. Targeted Drug Therapy
9.3.5. Others
9.4. Market Value Forecast, by Country, 2017‒2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Type
9.5.2. By Treatment
9.5.3. By Country
10. Europe Glioma Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017‒2031
10.2.1. Low-Grade
10.2.1.1. grade I
10.2.1.2. grade II
10.2.2. High-grade
10.2.2.1. grade III
10.2.2.2. grade IV
10.3. Market Value Forecast, by Treatment, 2017‒2031
10.3.1. Surgery
10.3.2. Radiation Therapy
10.3.3. Chemotherapy
10.3.4. Targeted Drug Therapy
10.3.5. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017‒2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Type
10.5.2. By Treatment
10.5.3. By Country/Sub-region
11. Asia Pacific Glioma Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017‒2031
11.2.1. Low-Grade
11.2.1.1. grade I
11.2.1.2. grade II
11.2.2. High-grade
11.2.2.1. grade III
11.2.2.2. grade IV
11.3. Market Value Forecast, by Treatment, 2017‒2031
11.3.1. Surgery
11.3.2. Radiation Therapy
11.3.3. Chemotherapy
11.3.4. Targeted Drug Therapy
11.3.5. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017‒2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Type
11.5.2. By Treatment
11.5.3. By Country/Sub-region
12. Latin America Glioma Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017‒2031
12.2.1. Low-Grade
12.2.1.1. grade I
12.2.1.2. grade II
12.2.2. High-grade
12.2.2.1. grade III
12.2.2.2. grade IV
12.3. Market Value Forecast, by Treatment, 2017‒2031
12.3.1. Surgery
12.3.2. Radiation Therapy
12.3.3. Chemotherapy
12.3.4. Targeted Drug Therapy
12.3.5. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017‒2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Type
12.5.2. By Treatment
12.5.3. By Country/Sub-region
13. Middle East & Africa Glioma Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017‒2031
13.2.1. Low-Grade
13.2.1.1. grade I
13.2.1.2. grade II
13.2.2. High-grade
13.2.2.1. grade III
13.2.2.2. grade IV
13.3. Market Value Forecast, by Treatment, 2017‒2031
13.3.1. Surgery
13.3.2. Radiation Therapy
13.3.3. Chemotherapy
13.3.4. Targeted Drug Therapy
13.3.5. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017‒2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Type
13.5.2. By Treatment
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis By Company (2021)
14.3. Company Profiles
14.3.1. Bristol-Myers Squibb Company
14.3.1.1. Company Overview
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Genentech, Inc. (F. Hoffmann-La Roche Ltd.
14.3.2.1. Company Overview
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Pfizer, Inc.
14.3.3.1. Company Overview
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Merck & Co., Inc
14.3.4.1. Company Overview
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Teva Pharmaceutical Industries Ltd
14.3.5.1. Company Overview
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Sun Pharmaceutical Industries Ltd.
14.3.6.1. Company Overview
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Amgen, Inc.
14.3.7.1. Company Overview
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Other prominent players
14.3.8.1. Company Overview
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
*Note: Financial details for companies that do not report this information in public domain might not be captured
List of Tables
Table 01: Global Glioma Treatment Market Value (US$ Mn) Forecasts, by Type, 2017–2031
Table 02: Global Glioma Treatment Market Value (US$ Mn) Forecast, by High-grade, 2017–2031
Table 03: Global Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade , 2017–2031
Table 04: Global Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 05: Global Glioma Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Glioma Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Glioma Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 08: North America Glioma Treatment Market Value (US$ Mn) Forecast, by High-grade, 2017–2031
Table 09: North America Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade, 2017–2031
Table 10: North America Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 11: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 13: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by High-grade, 2017–2031
Table 14: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade, 2017–2031
Table 15: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 16: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 18: Asia Pacific Glioma Treatment Market Analysis and Value (US$ Mn) Forecast, by High-grade, 2017–2031
Table 19: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade, 2017–2031
Table 20: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 21: Latin America Glioma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Latin America Glioma Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 23: Latin America Glioma Treatment Market and Value (US$ Mn) Forecast, by High-grade, 2017–2031
Table 24: Latin-America Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade , 2017–2031
Table 25: Latin America Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 26: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Country/Sub-region, 2017–2031
Table 27: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Type, 2017–2031
Table 28: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by High-grade, 2017–2031
Table 29: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Low-grade, 2017–2031
Table 30: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Treatment, 2017–2031
List of Figures
Figure 01: Global Glioma Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Glioma Treatment Market Value Share, by Type, 2021
Figure 03: Global Glioma Treatment Market Value Share, by Treatment, 2021
Figure 04: Global Glioma Treatment Market Value Share, by Region, 2021
Figure 05: 5-year Relative Survival Rate
Figure 06: Global Glioma Treatment Market, by Type, 2021 and 2031
Figure 07: Global Glioma Treatment Market Attractiveness Analysis, by Type, 2022–2031
Figure 08: Global Glioma Treatment Market (US$ Mn), by High-grade, 2017–2031
Figure 09: Global Glioma Treatment Market (US$ Mn), by Low-grade , 2017–2031
Figure 10: Global Glioma Treatment Market, by Treatment, 2021 and 2031
Figure 11: Global Glioma Treatment Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 12: Global Glioma Treatment Market (US$ Mn), by Surgery, 2017–2031
Figure 13: Global Glioma Treatment Market (US$ Mn), by Radiation Therapy , 2017–2031
Figure 14: Global Glioma Treatment Market (US$ Mn), by Chemotherapy, 2017–2031
Figure 15: Global Glioma Treatment Market (US$ Mn), by Targeted Drug therapy, 2017–2031
Figure 16: Global Glioma Treatment Market (US$ Mn), by Others, 2017–2031
Figure 17: Global Glioma Treatment Market, by Region, 2021 and 2031
Figure 18: Global Glioma Treatment Market Attractiveness Analysis, by Region, 2022–2031
Figure 19: North America Glioma Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 20: North America Glioma Treatment Market, By Country, 2021 And 2031
Figure 21: North America Glioma Treatment Market Attractiveness Analysis, by Country, 2022–2031
Figure 22: North America Glioma Treatment Market, by Type, 2021 and 2031
Figure 23: North America Glioma Treatment Market Attractiveness Analysis, by Type, 2022–2031
Figure 24: North America Glioma Treatment Market, by Treatment, 2021 and 2031
Figure 25: North America Glioma Treatment Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 26: Europe Glioma Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 27: Europe Glioma Treatment Market, by Country/Sub-region, 2021 and 2031
Figure 28: Europe Glioma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 29: Europe Glioma Treatment Market, by Type, 2021 and 2031
Figure 30: Europe Glioma Treatment Market Attractiveness Analysis, by Type, 2022–2031
Figure 31: Europe Glioma Treatment Market, by Treatment, 2021 and 2031
Figure 32: Europe Glioma Treatment Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 33: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 34: Asia Pacific Glioma Treatment Market, by Country/Sub-region, 2021 and 2031
Figure 35: Asia Pacific Glioma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 36: Asia Pacific Glioma Treatment Market, by Type, 2021 and 2031
Figure 37: Asia Pacific Glioma Treatment Market Attractiveness Analysis, by Type, 2022–2031
Figure 38:Asia Pacific Glioma Treatment Market, by Treatment, 2021 and 2031
Figure 39: Asia Pacific Glioma Treatment Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 40: Latin America Glioma Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 41: Latin America Treatment Market, by Country/Sub-region, 2021 and 2031
Figure 42: Latin America Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 43: Latin America Glioma Treatment Market, by Type, 2021 and 2031
Figure 44: Latin America Glioma Treatment Market Attractiveness Analysis, by Type, 2022–2031
Figure 45: Latin America Glioma Treatment Market, by Treatment, 2021 and 2031
Figure 46: Latin America Glioma Treatment Market Attractiveness Analysis, by Treatment, 2022–2031
Figure 47: Middle East & Africa Glioma Treatment Market Analysis, Value (US$ Mn) Forecast, 2017–2031
Figure 48: Middle East & Africa Glioma Treatment Market Analysis and Forecast, 2021 and 2031
Figure 49: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Country/Sub-region, 2022–2031
Figure 50: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Type, 2021 and 2031
Figure 51: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Type, 2022–2031
Figure 52: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Treatment, 2021-2031
Figure 53: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Treatment, 2022–2031
Figure 54: Global Glioma Treatment Market Share Analysis/Ranking, by Company, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Glioma Treatment Market
